SFCM
CTMX icon

Seven Fleet Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Seven Fleet Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
371,398
+322,500
+660% +$1.64M 0.55% 43
2025
Q4 		$208K Buy
+48,898
New +$186K 0.14% 64

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Seven Fleet Capital Management's CTMX Position: Q1 2026 in Review

Seven Fleet Capital Management increased its CytomX Therapeutics (CTMX) stake by 660% in Q1 2026, buying an estimated $1.64M and bringing the position to 371,398 shares worth $1.75M. The position accounts for 0.55% of the portfolio, ranked #43.

Seven Fleet Capital Management first reported a position in CTMX in Q4 2025 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Seven Fleet Capital Management held 371,398 shares of CytomX Therapeutics worth $1.75M as of Q1 2026.
  • Seven Fleet Capital Management bought 322,500 CytomX Therapeutics shares in Q1 2026, an estimated $1.64M.
  • CytomX Therapeutics made up 0.55% of Seven Fleet Capital Management's portfolio in Q1 2026, its #43 holding.
  • Seven Fleet Capital Management first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.